AdvanCell Isotopes
AdvanCell Isotopes is a Healthcare & Life Sciences startup based in Boston, the United States, most recent round Series C+, 3 tracked investors.
About AdvanCell Isotopes
AdvanCell Isotopes is a startup founded in 2020 based in Boston, the United States. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 3 investors associated with the company.
AdvanCell Isotopes is an Australian company developing 212Pb-based targeted alpha radiotherapeutics and operates a 212Pb isotope manufacturing capability; it is advancing a 212Pb PSMA-targeting radioligand for prostate cancer alongside a pipeline of radiotherapeutic programs.
Explore AdvanCell Isotopes's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.